Content uploaded by Adonis Sfera
Author content
All content in this area was uploaded by Adonis Sfera on Sep 03, 2022
Content may be subject to copyright.
The Matryoshka code of COVID-19 mRNA vaccines: overlapping viral
sequences?
Adonis Sfera1, 2*, Sabine Hazan1, Dan O. Sfera1, Zisis Kozlakidis3
1Patton State Hospital, United States, 2University of California,
Riverside, United States, 3International Agency For Research On Cancer
(IARC), France
Submitted to Journal:
Frontiers in Immunology
Specialty Section:
Viral Immunology
Article type:
General Commentary Article
Manuscript ID:
1035520
Received on:
02 Sep 2022
Journal website link:
www.frontiersin.org
We read with great interest the paper by Beaudoin CA et al. “Are There
Hidden Genes in DNA/RNA Vaccines?”, reporting overlapping
sequences between the SARS-CoV-2 spike (S) glycoprotein and two viral
genes (1). If translated, the undesired proteins may cause rare,
untoward effects, including those recorded in Vaccine Adverse Event
Reporting System (VAERS).
These findings are in line with our own research and that of others
however, aside from overlapping genes (OLGs), the S protein also
contains overlapping molecular structures and signals (heptad repeats,
simple sequence repeats, calcium calmodulin kinase II, and prion-like
domains) that can lead to VAERS-recorded pathology (2-6).
Overlapping genetic and structural information are important to
viruses, as they maximize the number of translated proteins derived
from the same genetic information (7). This compact arrangement also
allows for the emergence of mutations without major genetic
restructuring (8). Furthermore, there is evidence that such structures
also regulate gene expression in many viruses (9), including
coronaviruses (10-11)(Fig. 1).
Taking the above viral-derived complication into account, messenger
RNA (mRNA) vaccines encode the full-length S protein that when
expressed on the surface of cells, prompts the generation of
neutralizing antibodies (12). Thus, both OLGs and molecular systems
may be translated too, contributing to vaccine complications and
potential adverse effects.
Fig. 1 The overlapping molecular structures and signals in the S protein of SARS-CoV-2 virus.
Glycosylation is a viral strategy for successfully exploiting host translational machinery.
Vaccination with SARS-CoV-2 S protein lacking glycan shields elicits enhanced responses
therefore, glycosylation may have been altered in mRNA vaccines. RBD (receptor binding
domain), CaMKII (calcium calmodulin kinase II), SSR(simple sequence repeats).
Messenger RNA vaccines, known modifications
To elicit the generation of neutralizing antibodies, exogenously
administered mRNA must be heavily engineered to avoid hydrolysis by
the extracellular RNAases and detection by cytosolic immune sensors
(13-14). Placing the nucleic acid backbone into lipid nanoparticles
(LNPs), hides it from RNAases, while codon optimization, replacing
uridine with N1-methylpseudouridine (m1Ψ), renders the vaccine
undetectable to sensors (15-16). Other adjustments were made in the
untranslated regions (UTRs) and polyadenylated (polyA) tail to protect
and stabilize the vaccine (14)(16-17). Another known change, addition
of two proline residues, maintain the S antigen in prefusion
conformation to augment immune system exposure (18). Moreover,
aside from m1Ψ, codon optimization includes increased the CG content
and possibly G-quadruplex structures to enhance translation (6).
Potential unknown changes
Aside from the reported changes, the mRNA encoded S antigen may
have been engineered further to increase efficacy and translation.
Sense codon reassignment?
Pfizer/BioNTech has published the mRNA vaccine sequences, allowing
scientists and clinicians to compare codons with the wild type S protein.
However, the translated peptides remain proprietary therefore, at this
time, it is not possible to rule out sense codon reassignment or
introduction of unnatural proteins (19). This is important as genetic
code expansion and incorporation of immunogenic noncanonical amino
acids, patented in 2018 (WO2019193416A1), were evaluated for
utilization in genetic vaccines (20). Some unnatural amino acids,
especially homoarginine, was associated with heart disease and sudden
death therefore, these artificial building blocks may in rare occasions
directly contribute to VAERS-recorded events (21-22).
Sugar coating or not?
It is unknown at this time whether the S protein glycans were altered to
increase the efficacy of the mRNA therapeutics. However, vaccine-
elicited neutralizing antibodies exhibit a distinct glycosylation pattern
than post-infection antibodies, indicating possible manipulation (23-
25). This is significant as glycosylation plays a major role in
cardiovascular and endothelial homeostasis, providing a potential link
to VAERS-recorded events (26-27)(Fig. 1).
The S antigen molecular systems
Several biomolecular systems are present in the S protein of SARS-CoV-
2 that when translated may trigger secondary pathways linked to
vaccine adverse effects. These systems include simple sequence
repeats, heptad repeats, calcium calmodulin kinase II, and prion-like
domains (3-6). Translation of these molecular structures may lead to
new viral variants, pathological cell-cell fusion, and defective
proteostasis. These potential links, derived from the viral legacy of
overlapping genetic and structural information will be briefly presented
below:
-Simple sequence repeats (SSRs)
Also called microsatellites, SSRs are present in the genomes of many
viruses, including SARS-CoV-2, accounting for a number of the new,
emerging variants (28-29). Trinucleotide and hexanucleotide repeats
are the most common SSRs that, aside from their role in viral genomes,
contribute to skeletal muscle pathology and neurodegeneration,
possibly explaining vaccine-induced neuropsychiatric and
neuromuscular symptoms (30-31). Interestingly, SSRs are influenced by
the CG content of nucleic acids which is elevated in COVID-19 mRNA
vaccines, linking these therapeutics to the emergence of new variants
(32-33).
The DNA mismatch repair factor, MSH3, previously associated with
trinucleotide repeats, was also found to function as a sensor for G-
quadruplexes therefore, opposing codon optimization (34-35). This is
interesting as a novel study found a proprietary, Moderna-owned,
reverse MSH3 sequence that matches the SARS-CoV-2 furin cleavage
site, suggesting an OLG (36). Indeed, to protect the optimized CG
content and G-quadruplexes, MSH3 may need to be attenuated or
inhibited, explaining the reason this reverse sequence could have been
patented (US-9587003-B2).
-Heptad repeats
There are two heptad repeats in the S protein of SARS-CoV-2 that
assemble into a six-helix bundle to execute membrane fusion (37).
Translation of these structures likely accounts for vaccine-induced
pathological cell-cell fusion, that could result in rare post-vaccination
events, such as giant cell myocarditis (38-39).
-Calcium calmodulin kinase II
Cell-cell fusion can also be promoted by calcium calmodulin kinase II
(CaMKII), a system detected in the S antigen of the SARS-CoV-2 virus
(4). CaMKII may promote post-vaccination pathological syncytia,
probably accounting for VAERS-reported multinucleated giant cells
thyroiditis or myocarditis (4)(40).
-Prion-like domains
The receptor-binding domain (RBD) of the SARS-CoV-2 virus contains a
prion motif that could be translated, leading to pathology (5). Indeed,
post-vaccination Creutzfeldt-Jakob disease (CJD) was reported by two
separate studies, indicating that the prion motif may get translated (41-
42).
In summary
OLG and overlapping molecular structures are common occurrence in
viruses and contribute to a number of biological processes. However,
such overlapping information may also be translated with the vaccine
mRNA, thus inadvertently increasing the odds of pathology. An mRNA
vaccine expressing only the RBD may lower the susceptibility for
adverse effects.
Disclaimer:
Where authors are identified as personnel of the International Agency
for Research on Cancer/WHO, the authors alone are responsible for the
views expressed in this article and they do not necessarily represent the
decisions, policy or views of the International Agency for Research on
Cancer/WHO.
References:
1. Beaudoin CA, Bartas M, Volná A, Pečinka P, Blundell TL. Are There
Hidden Genes in DNA/RNA Vaccines? Front Immunol. 2022 Feb
8;13:801915. doi: 10.3389/fimmu.2022.801915. PMID: 35211117;
PMCID: PMC8860813.
2. Osorio C, Sfera A, Anton JJ, Thomas KG, Andronescu CV, Li E, Yahia
RW, Avalos AG, Kozlakidis Z. Virus-Induced Membrane Fusion in
Neurodegenerative Disorders. Front Cell Infect Microbiol. 2022
Mar 24;12:845580. doi: 10.3389/fcimb.2022.845580. PMID:
35531328; PMCID: PMC9070112.
3. Garushyants SK, Rogozin IB, Koonin EV. Template switching and
duplications in SARS-CoV-2 genomes give rise to insertion variants
that merit monitoring. Commun Biol. 2021 Nov 30;4(1):1343. doi:
10.1038/s42003-021-02858-9. PMID: 34848826; PMCID:
PMC8632935.
4. Wenzhong L, Hualan L. COVID-19: the CaMKII-like system of S
protein drives membrane fusion and induces syncytial
multinucleated giant cells. Immunol Res. 2021 Dec;69(6):496-519.
doi: 10.1007/s12026-021-09224-1. Epub 2021 Aug 19. PMID:
34410575; PMCID: PMC8374125.
5. Tetz G, Tetz V. Prion-like Domains in Spike Protein of SARS-CoV-2
Differ across Its Variants and Enable Changes in Affinity to ACE2.
Microorganisms. 2022 Jan 25;10(2):280. doi:
10.3390/microorganisms10020280. PMID: 35208734; PMCID:
PMC8878784.
6. Xia X. Detailed Dissection and Critical Evaluation of the
Pfizer/BioNTech and Moderna mRNA Vaccines. Vaccines (Basel).
2021 Jul 3;9(7):734. doi: 10.3390/vaccines9070734. PMID:
34358150; PMCID: PMC8310186.
7. Schlub TE, Holmes EC. Properties and abundance of overlapping
genes in viruses. Virus evolution. 2020 Jan;6(1):veaa009.
8. Cassan E. et al. (2016) ‘Concomitant Emergence of the Antisense
Protein Gene of HIV-1 and of the Pandemic’, Proceedings of the
National Academy of Sciences of the United States of America,
113: 11537-42.
9. Han L. L. et al. (2017) ‘Genetic and Functional Diversity of
Ubiquitous DNA Viruses in Selected Chinese Agricultural Soils’,
Scientific Reports, 7: 45142
10. Okura T, Shirato K, Kakizaki M, Sugimoto S, Matsuyama S,
Tanaka T, Kume Y, Chishiki M, Ono T, Moriishi K, Sonoyama M.
Hydrophobic Alpha-Helical Short Peptides in Overlapping Reading
Frames of the Coronavirus Genome. Pathogens. 2022 Aug
3;11(8):877.
11. Firth AE. A putative new SARS-CoV protein, 3c, encoded in
an ORF overlapping ORF3a. The Journal of general virology. 2020
Oct;101(10):1085.
12. Turner JS, O’Halloran JA, Kalaidina E, Kim W, Schmitz AJ,
Zhou JQ, Lei T, Thapa M, Chen RE, Case JB, Amanat F. SARS-CoV-2
mRNA vaccines induce persistent human germinal centre
responses. Nature. 2021 Aug;596(7870):109-13.
13. Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN,
Kitada T. N(1)-methylpseudouridine-incorporated mRNA
outperforms pseudouridine-incorporated mRNA by providing
enhanced protein expression and reduced immunogenicity in
mammalian cell lines and mice. J Control Release. 2015;217:337-
344.
14. Schoenmaker L, Witzigmann D, Kulkarni JA, et al. mRNAlipid
nanoparticle COVID-19 vaccines: Structure an stability. Int J
Pharm. 2021;601:120586.
15. Nance KD, Meier JL. Modifications in an Emergency: The
Role of N1-Methylpseudouridine in COVID-19 Vaccines. ACS Cent
Sci. 202;7(5):748-756.
16. Gebre MS, Rauch S, Roth N, et al. Optimization of non-
coding regions for a non-modified mRNA COVID-19 vaccine.
Nature. 2022;601(7893):410-414.
17. Jeeva S, Kim KH, Shin CH, Wang BZ, Kang SM. An Update on
mRNA-Based Viral Vaccines. Vaccines (Basel). 2021;9(9):965.
18. Riley TP, Chou HT, Hu R, Bzymek KP, Correia AR, Partin AC, Li
D, Gong D, Wang Z, Yu X, Manzanillo P, Garces F. Enhancing the
Prefusion Conformational Stability of SARS-CoV-2 Spike Protein
Through Structure-Guided Design. Front Immunol. 2021 Apr
22;12:660198. doi: 10.3389/fimmu.2021.660198.
19. Theoharides TC. Could SARS-CoV-2 Spike Protein Be
Responsible for Long-COVID Syndrome? Mol Neurobiol. 2022
Mar;59(3):1850-1861. doi: 10.1007/s12035-021-02696-0. Epub
2022 Jan 13. PMID: 35028901; PMCID: PMC8757925.
20. Fok JA, Mayer C. Genetic-Code-Expansion Strategies for
Vaccine Development. Chembiochem. 2020 Dec 1;21(23):3291-
3300. doi: 10.1002/cbic.202000343. Epub 2020 Jul 30. PMID:
32608153; PMCID: PMC7361271.
21. März W, Meinitzer A, Drechsler C, Pilz S, Krane V, Kleber ME,
Fischer J, Winkelmann BR, Böhm BO, Ritz E, Wanner C.
Homoarginine, cardiovascular risk, and mortality. Circulation.
2010 Sep 7;122(10):967-75. doi:
10.1161/CIRCULATIONAHA.109.908988.
22. Drechsler C, Meinitzer A, Pilz S, Krane V, Tomaschitz A, Ritz
E, März W, Wanner C. Homoarginine, heart failure, and sudden
cardiac death in haemodialysis patients. Eur J Heart Fail. 2011
Aug;13(8):852-9. doi: 10.1093/eurjhf/hfr056.
23. Grant, O.C., Montgomery, D., Ito, K. et al. Analysis of the
SARS-CoV-2 spike protein glycan shield reveals implications for
immune recognition. Sci Rep 10, 14991 (2020).
https://doi.org/10.1038/s41598-020-71748-7
24. Zhao X, Chen H, Wang H. Glycans of SARS-CoV-2 Spike
Protein in Virus Infection and Antibody Production. Front Mol
Biosci. 2021 Apr 13;8:629873. doi: 10.3389/fmolb.2021.629873.
PMID: 33928117; PMCID: PMC8076860.
25. Farkash I, Feferman T, Cohen-Saban N, Avraham Y,
Morgenstern D, Mayuni G, et al. Anti-SARS-CoV-2 antibodies
elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation
pattern. Cell Rep. 2021 Dec 14;37(11):110114. doi:
10.1016/j.celrep.2021.110114.
26. Franzka P, Krüger L, Schurig MK, Olecka M, Hoffmann S,
Blanchard V, Hübner CA. Altered Glycosylation in the Aging Heart.
Front Mol Biosci. 2021 May 28;8:673044. doi:
10.3389/fmolb.2021.673044.
27. Chacko BK, Scott DW, Chandler RT, Patel RP. Endothelial
surface N-glycans mediate monocyte adhesion and are targets for
anti-inflammatory effects of peroxisome proliferator-activated
receptor γ ligands. J Biol Chem. 2011 Nov 4;286(44):38738-38747.
doi: 10.1074/jbc.M111.247981.
28. Siddiqe R, Ghosh A. Genome-wide in silico identification and
characterization of Simple Sequence Repeats in diverse
completed SARS-CoV-2 genomes. Gene Rep. 2021 Jun;23:101020.
doi: 10.1016/j.genrep.2021.101020.
29. Naghibzadeh M, Savari H, Savadi A, Saadati N, Mehrazin E.
Developing an ultra-efficient microsatellite discoverer to find
structural differences between SARS-CoV-1 and Covid-19. Inform
Med Unlocked. 2020;19:100356. doi: 10.1016/j.imu.2020.100356.
Epub 2020 May 21. Erratum in: Inform Med Unlocked.
2020;20:100435. PMID: 32501423; PMCID: PMC7241407.
30. Lieberman AP, Shakkottai VG, Albin RL. Polyglutamine
Repeats in Neurodegenerative Diseases. Annu Rev Pathol. 2019
Jan 24;14:1-27. doi: 10.1146/annurev-pathmechdis-012418-
012857.
31. Yum K, Wang ET, Kalsotra A. Myotonic dystrophy: disease
repeat range, penetrance, age of onset, and relationship between
repeat size and phenotypes. Curr Opin Genet Dev. 2017
Jun;44:30-37. doi: 10.1016/j.gde.2017.01.007.
32. Qi WH, Yan CC, Li WJ, Jiang XM, Li GZ, Zhang XY, Hu TZ, Li J,
Yue BS. Distinct patterns of simple sequence repeats and GC
distribution in intragenic and intergenic regions of primate
genomes. Aging (Albany NY). 2016 Sep 16;8(11):2635-2654. doi:
10.18632/aging.101025.
33. Ouyang Q, Zhao X, Feng H, Tian Y, Li D, Li M, Tan Z. High GC
content of simple sequence repeats in Herpes simplex virus type 1
genome. Gene. 2012 May 10;499(1):37-40. doi:
10.1016/j.gene.2012.02.049.
34. Flower M, Lomeikaite V, Ciosi M, Cumming S, Morales F, Lo
K, et al. MSH3 modifies somatic instability and disease severity in
Huntington's and myotonic dystrophy type 1. Brain. 2019 Jun
19;142(7):1876–86. doi: 10.1093/brain/awz115.
35. Fleming, A.M.; Burrows, C.J. Interplay of Guanine Oxidation
and G-Quadruplex Folding in Gene Promoters. J. Am. Chem. Soc.
2020, 142, 1115–1136
36. Ambati BK, Varshney A, Lundstrom K, Palú G, Uhal BD,
Uversky VN, et al. MSH3 Homology and Potential Recombination
Link to SARS-CoV-2 Furin Cleavage Site. Front. Virol., 21 February
2022. https://doi.org/10.3389/fviro.2022.834808
37. Hu, B., Guo, H., Zhou, P. et al. Characteristics of SARS-CoV-2
and COVID-19. Nat Rev Microbiol 19, 141–154 (2021).
https://doi.org/10.1038/s41579-020-00459-7
38. Sung K, McCain J, King KR, Hong K, Aisagbonhi O, Adler ED,
Urey MA. Biopsy-Proven Giant Cell Myocarditis Following the
COVID-19 Vaccine. Circ Heart Fail. 2022 Apr;15(4):e009321. doi:
10.1161/CIRCHEARTFAILURE.121.009321.
39. Kang DH, Na JY, Yang JH, Moon SH, Kim SH, Jung JJ, et al.
Fulminant Giant Cell Myocarditis following Heterologous
Vaccination of ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19.
Medicina (Kaunas). 2022 Mar 20;58(3):449. doi:
10.3390/medicina58030449.
40. Bornemann C, Woyk K, Bouter C. Case Report: Two Cases of
Subacute Thyroiditis Following SARS-CoV-2 Vaccination. Front
Med (Lausanne). 2021 Aug 24;8:737142. doi:
10.3389/fmed.2021.737142. PMID: 34504856; PMCID:
PMC8421599.
41. Creutzfeldt-Jakob Disease After the COVID-19 Vaccination.
Turk J Intensive Care. DOI: 10.4274/tybd.galenos.2021.91885
42. Jean claude Perez, claire Moret-Chalmin, & RIP Luc
Montagnier. (2022). Towards the emergence of a new form of the
neurodegenerative Creutzfeldt-Jakob disease: Twenty six cases of
CJD declared a few days after a COVID-19 "vaccine" Jab (Version
V4). Zenodo. https://doi.org/10.5281/zenodo.6641999